MoonLake Immunotherapeutics CEO Jorge Santos da Silva (L) and CSO Kristian Reich (via website)
July 17, 2023 06:44 AM EDTUpdated 06:55 AM
Deals
Pharma

Moon­Lake’s im­munol­o­gy drug gets help of in­vest­ment bankers for po­ten­tial sale — Reuters re­port

Kyle LaHucik

Senior Reporter

Moon­Lake Im­munother­a­peu­tics is work­ing with an in­vest­ment bank to ex­plore a po­ten­tial sale, per a Fri­day evening re­port in Reuters, cit­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times